Brivaracetam;UCB 34714;UCB-34714;UCB34714; Briviact

CAS NO.:357336-20-0

分子式:C₁₁H₂₀N₂O₂

分子量:212.2887

纯度: > 98%

溶解性: (R.T.: 25℃): DMSO

稳定性: - 20℃ 3 years

Brivaracetam has been tested in a comprehensive safety pharmacology, toxicology, developmental toxicology, and genotoxicity program. It is of low acute toxicity, target organ for toxic effects is the hepatobiliary tract. Carcinogenicity studies are ongoing. Human pharmacology studies have shown that brivaracetam has a half-life of 8 h and nearly complete bioavailability . CSD episodes were regularly elicited on slices upon delivery of calibrated KCl drops and were recorded via two micropipette electrodes. After control CSDs, the drug was added to the perfusion and five subsequent CSDs were elicited during drug perfusion. Effects were assessed via CSD amplitude (Ampl) and duration at half-amplitude (D(1/2)). BRV, 10 and 32 microM reduced the Ampl and transiently the D(1/2). Levetiracetam, 32 and 100 microM had no effect on either Ampl or D(1/2) . Brivaracetam bound selectively with 20 fold higher affinity than levetiracetam to SV2A . BRV produced a concentration-dependent inhibition of

可提供多种规格，大量可定制；

如需更多规格的报价，请点击询价或者通过在线QQ及电子邮件联系！

当前批次纯度大于98%，产品COA和相关检测报告可提供电子版或随货发出；
所有可选规格：常温运输或根据产品特性加蓝冰运输。
本公司所有产品仅供实验科研使用，不为任何个人提供产品和服务。